If a fibrinolytic drug is used for the treatment of acute myocardial infarction, the adverse effect most likely to occur is:
Bleeding is the most common adverse effect of anticoagulants, antiplatelets and fibrinolytic agents. Bleeding can manifest as hemorrhagic stroke in pts. on fibrinolytics therapy such as- Alteplase, Retaplase, Streptokinase. C/I of Fibrinolytics :- H/O Hemorrhagic Stroke H/O NON Hemorrhagic Stroke (within 1yr) Suspicion of aoic dissection Marked hypeension (SBP>180mm Hg and DBP>110mm Hg) Active internal bleed (Excluding menses)
Acute renal failure
Development of antiplatelet antibodies
Encephalitis secondary to liver dysfunction
Hemorrhagic stroke
Hematology